The significance of acid/base properties in drug discovery.

While drug discovery scientists take heed of various guidelines concerning drug-like character, the influence of acid/base properties often remains under-scrutinised. Ionisation constants (pK(a) values) are fundamental to the variability of the biopharmaceutical characteristics of drugs and to underlying parameters such as logD and solubility. pK(a) values affect physicochemical properties such as aqueous solubility, which in turn influences drug formulation approaches. More importantly, absorption, distribution, metabolism, excretion and toxicity (ADMET) are profoundly affected by the charge state of compounds under varying pH conditions. Consideration of pK(a) values in conjunction with other molecular properties is of great significance and has the potential to be used to further improve the efficiency of drug discovery. Given the recent low annual output of new drugs from pharmaceutical companies, this review will provide a timely reminder of an important molecular property that influences clinical success.

[1]  Gordon M. Crippen,et al.  Predicting p K a . , 2009 .

[2]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[3]  Yvonne Will,et al.  The significance of mitochondrial toxicity testing in drug development. , 2007, Drug discovery today.

[4]  I. Collins,et al.  Enhancement of oral absorption in selective 5-HT1D receptor agonists: fluorinated 3-[3-(piperidin-1-yl)propyl]indoles. , 1998, Journal of medicinal chemistry.

[5]  Maurizio Recanatini,et al.  hERG-related drug toxicity and models for predicting hERG liability and QT prolongation , 2009, Expert opinion on drug metabolism & toxicology.

[6]  Kiyohiko Sugano,et al.  Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. , 2006, The Journal of toxicological sciences.

[7]  J. Peters,et al.  Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.

[8]  M. Hann.  Molecular obesity, potency and other addictions in drug discovery , 2011 .

[9]  John Manchester,et al.  Evaluation of pKa Estimation Methods on 211 Druglike Compounds , 2010, J. Chem. Inf. Model..

[10]  K. Luthman,et al.  Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. , 1999, The Journal of pharmacology and experimental therapeutics.

[11]  M Paul Gleeson,et al.  In silico human and rat Vss quantitative structure-activity relationship models. , 2006, Journal of medicinal chemistry.

[12]  B. Brodie,et al.  Absorption of drugs from the rat small intestine. , 1958, The Journal of pharmacology and experimental therapeutics.

[13]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[14]  T. Sjögren,et al.  Structural basis for ligand promiscuity in cytochrome P450 3A4 , 2006, Proceedings of the National Academy of Sciences.

[15]  P A Carrupt,et al.  Evaluation and Prediction of Drug Permeation , 1999, The Journal of pharmacy and pharmacology.

[16]  D. Manallack.  The acid–base profile of a contemporary set of drugs: implications for drug discovery , 2009, SAR and QSAR in environmental research.

[17]  R. Prankerd.  Critical Compilation of pK(a) Values for Pharmaceutical Substances. , 2007, Profiles of drug substances, excipients, and related methodology.

[18]  R. Capaldi,et al.  Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. , 2007, Toxicology and applied pharmacology.

[19]  J. Corradi,et al.  Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. , 2010, Chemical research in toxicology.

[20]  Valentino J. Stella,et al.  Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists , 1979 .

[21]  Paul D. Leeson,et al.  Impact of ion class and time on oral drug molecular properties , 2011 .

[22]  Jingwei Shao,et al.  Compilation of 222 drugs' plasma protein binding data and guidance for study designs. , 2012, Drug discovery today.

[23]  John P. Overington,et al.  Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.

[24]  P. Andrews,et al.  Functional group contributions to drug-receptor interactions. , 1984, Journal of medicinal chemistry.

[25]  Roy J Vaz,et al.  Human ether-a-go-go related gene (HERG): a chemist's perspective. , 2005, Progress in medicinal chemistry.

[26]  D. E. Clark.  In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.

[27]  Emanuele Perola,et al.  An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.

[28]  M Paul Gleeson,et al.  Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. , 2007, Journal of medicinal chemistry.

[29]  M. Edwards,et al.  Using the Golden Triangle to optimize clearance and oral absorption. , 2009, Bioorganic & medicinal chemistry letters.

[30]  Tudor I. Oprea,et al.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS. , 2012, Advanced drug delivery reviews.

[31]  Jan Kelder,et al.  Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[32]  Nigel Greene,et al.  Evaluation of a Published in Silico Model and Construction of a Novel Bayesian Model for Predicting Phospholipidosis Inducing Potential , 2007, J. Chem. Inf. Model..

[33]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[34]  Christian Skonberg,et al.  Metabolic activation of carboxylic acids , 2008 .

[35]  Y. Martin,et al.  A bioavailability score. , 2005, Journal of medicinal chemistry.

[36]  A. Seelig.  A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.

[37]  David J.W. Grant,et al.  Solubility behavior of organic compounds , 1990 .

[38]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[39]  Yvonne C. Martin,et al.  Let’s not forget tautomers , 2009, J. Comput. Aided Mol. Des..

[40]  T. Maurer,et al.  Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery , 2002, Biopharmaceutics & drug disposition.

[41]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[42]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[43]  M. Waring,et al.  A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.

[44]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[45]  Ilme Schlichting,et al.  Structure and chemistry of cytochrome P450. , 2005, Chemical reviews.

[46]  M. Boisset,et al.  Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: importance of drug ionisation in the in vitro prediction of in vivo absorption. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[47]  Nigel Greene,et al.  The development of structure-activity relationships for mitochondrial dysfunction: uncoupling of oxidative phosphorylation. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[48]  Leslie Z Benet,et al.  The drug transporter-metabolism alliance: uncovering and defining the interplay. , 2009, Molecular pharmaceutics.

[49]  Vijay K Gombar,et al.  Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. , 2004, Journal of pharmaceutical sciences.

[50]  A. Seelig,et al.  Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion , 1998, The Journal of Membrane Biology.

[51]  Remigijus Didziapetris,et al.  Classification Analysis of P-Glycoprotein Substrate Specificity , 2003, Journal of drug targeting.

[52]  O. Hucke,et al.  Development of Specific “Drug‐Like Property” Rules for Carboxylate‐Containing Oral Drug Candidates , 2010, ChemMedChem.

[53]  Edward H. Kerns,et al.  Insights for Predicting Blood-Brain Barrier Penetration of CNS Targeted Molecules Using QSPR Approaches , 2010, J. Chem. Inf. Model..

[54]  Tudor I. Oprea,et al.  A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. , 2011, Journal of medicinal chemistry.

[55]  N. Meanwell.  Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.

[56]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[57]  Paul D. Leeson,et al.  The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.

[58]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.